Replimune

Replimune, based in Woburn, Massachusetts, and listed as REPL, is the oncolytic virus company whose RP1, or vusolimogene oderparepvec, was approved in August 2026 as Tudriqev after an initial FDA rejection. RP1 is an oncolytic virus for melanoma and cutaneous squamous cell carcinoma, and RP2, which expresses an anti-CTLA-4 antibody, is being tested in uveal melanoma. OnCo links it to melanoma and cutaneous squamous cell carcinoma, to the oncolytic virus technology, to the bottleneck of cold tumours, and to the idea of oncolytic viruses that make interleukin-12 only inside the tumour. Whether an approval won after a rejection translates into adoption alongside checkpoint inhibitors is the open question. Vusolimogene oderparepvec has its own page.